摘要
OBJECTIVE: The aim of this study was to explore the possible (joint) contrib ut ing role of interleukin-6 (IL-6) and antiphospholipid antibodies to the occurr ence of the venous thromboembolism in women using oral contraceptives. METHODS: Interleukin-6 and antiphospholipid antibodies (anti-β2-glycoprotein I antibo dy-immunoglobulin M [IgM], G [IgG], and A [IgA]; anticardiolipin-IgM and IgG; antiphospha-tidylserine-IgM and IgG) were measured in 30 women (median age 41, range 28-49 years) in the stable period (on average 3.5 years) after first ven ous thromboembolism. Sixteen patients used oral contraceptives during the episod e of venous thromboembolism (oral contraceptives group), whereas 14 patients did not (non-oral contraceptives group). Thirty-seven age-matched, healthy women served as controls RESULTS: Compared with controls, the oral contraceptives gro up had elevated IL-6 (median interquartile range 2.3 [1.1-4.3] versus 1.4 [0- 2.0] pg/mL, P < .05). The oral contracepti ves group had elevated anti-β2-glycoprotein I antibody-IgM in comparison wit h both the non-oral contraceptives group (median interquartile range 47.5 [2.0 -77.0] versus 29.50 [11.00-45.50] OD450,P < .06) and controls (47.5 [2.0-77.0 ] versus 17.5 [3.5-30.0] OD450,P < .001). Interleukin-6 level in the non-oral contraceptives group was related to obesity, whereas such a relation was not fo und in the oral contraceptives group, suggesting the presence of another factor (oral contraceptive use), which stimulates IL-6 production. Of particular inter est is our finding that elevated IL-6 levels correlated significantly positivel y with elevated anti-β2-glycoprotein I antibody-IgG in patients who were use rs of oral contraceptives (but not overweight, n = 10) (r = 0.56, P < .05). CONC LUSION: The results suggest a new hypothesis that, in susceptible women, use of oral contraceptives induces production of IL-6, which stimulates production of anti-β2-glycoprotein I. Thus, the prothrombotic profile is aggravated and cou ld facilitate occurrence of venous thromboembolism. This remains to be elucidate d in further studies.
OBJECTIVE: The aim of this study was to explore the possible (joint) contrib ut ing role of interleukin-6 (IL-6) and antiphospholipid antibodies to the occurr ence of the venous thromboembolism in women using oral contraceptives. METHODS: Interleukin-6 and antiphospholipid antibodies (anti-β2-glycoprotein I antibo dy-immunoglobulin M [IgM], G [IgG], and A [IgA]; anticardiolipin-IgM and IgG; antiphospha-tidylserine-IgM and IgG) were measured in 30 women (median age 41, range 28-49 years) in the stable period (on average 3.5 years) after first ven ous thromboembolism. Sixteen patients used oral contraceptives during the episod e of venous thromboembolism (oral contraceptives group), whereas 14 patients did not (non-oral contraceptives group). Thirty-seven age-matched, healthy women served as controls RESULTS: Compared with controls, the oral contraceptives gro up had elevated IL-6 (median interquartile range 2.3 [1.1-4.3] versus 1.4 [0- 2.0] pg/mL, P < .05). The oral contracepti ves group had elevated anti-β2-glycoprotein I antibody-IgM in comparison wit h both the non-oral contraceptives group (median interquartile range 47.5 [2.0 -77.0] versus 29.50 [11.00-45.50] OD450,P < .06) and controls (47.5 [2.0-77.0 ] versus 17.5 [3.5-30.0] OD450,P < .001). Interleukin-6 level in the non-oral contraceptives group was related to obesity, whereas such a relation was not fo und in the oral contraceptives group, suggesting the presence of another factor (oral contraceptive use), which stimulates IL-6 production. Of particular inter est is our finding that elevated IL-6 levels correlated significantly positivel y with elevated anti-β2-glycoprotein I antibody-IgG in patients who were use rs of oral contraceptives (but not overweight, n = 10) (r = 0.56, P < .05). CONC LUSION: The results suggest a new hypothesis that, in susceptible women, use of oral contraceptives induces production of IL-6, which stimulates production of anti-β2-glycoprotein I. Thus, the prothrombotic profile is aggravated and cou ld facilitate occurrence of venous thromboembolism. This remains to be elucidate d in further studies.
